1.Effects of Tumor Necrosis Factor Alpha Blocker Adalimumab in Experimental Spinal Cord Injury.
Alp Ozgun BORCEK ; Soner CIVI ; Ozgur OCAL ; Ozlem GULBAHAR
Journal of Korean Neurosurgical Society 2015;57(2):73-76
OBJECTIVE: Tumor necrosis factor alpha (TNF-alpha) have proven effects in pathogenesis of neuroinflammation after spinal cord injury (SCI). Current study is designed to evaluate the effects of an anti-TNF-alpha agent, adalimumab, on spinal cord clip compression injury in rats. METHODS: Thirty two male adult Wistar rats were divided into four groups (sham, trauma, infliximab, and adalimumab groups) and SCI was introduced using an aneurysm clip. Animals in treatment groups received 5 mg/kg subcutaneous adalimumab and infliximab right after the trauma. Malondialdehyde (MDA) levels were studied in traumatized spinal cord tissues 72 hours after the injury as a marker of lipid peroxidation. RESULTS: Animals that received anti-TNF-alpha agents are found to have significantly decreased MDA levels. MDA levels were significantly different between the trauma and infliximab groups (p<0.01) and trauma and adalimumab groups (p=0.022). There was no significant difference in neurological evaluation of the rats using Tarlov scale. CONCLUSION: These results suggest that, like infliximab, adalimumab has favorable effects on lipid peroxidation induced by spinal cord trauma in rats.
Adult
;
Aneurysm
;
Animals
;
Humans
;
Lipid Peroxidation
;
Male
;
Malondialdehyde
;
Rats
;
Rats, Wistar
;
Spinal Cord
;
Spinal Cord Injuries*
;
Tumor Necrosis Factor-alpha*
;
Adalimumab
;
Infliximab